Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
The regulator HIF1α functions in a cancer-microenvironment that lacks oxygen, and it may be involved in resistance to immune checkpoint blockade therapy.
There are no effective antivirals against BK polyomavirus in transplanted kidneys. A better understanding of its replication will offer new ways to protect those kidneys.
Heart failure is responsible for 13 percent of deaths worldwide, and half of patients die within 5 years. New therapies are needed.
This polygenic score predicts tamoxifen treatment resistance is better than conventional methods, with potential for personalized medicine application.
Human proteins identified that explain inter-individual differences in functional brain connectivity
This is a step toward an understanding of the brain that ultimately describes the mechanistic basis of human cognition and behavior.
Bacterial viruses, known as phages, are the most abundant biological entities on the planet and are increasingly used as biomedicines to eradicate antibiotic-resistant pathogenic bacteria.
The National Institute on Drug Abuse award is designed to stimulate innovation and potentially transformative research from early stage investigators.
By showing a critical role for sialylation in the biophysical properties of mucus and mucus transport, the study identifies a possible therapeutic target for the treatment of cystic fibrosis and other muco-obstructive diseases.
The NIH grant will support development of a BionanomatrixTM coating for an aneurysm-therapy flow diverter in the brain.
The grant will develop a credentialed curriculum for a career path in research administration and grants management.